Fate Therapeutics Inc

NASDAQ:FATE   3:59:53 PM EDT
32.90
-3.16 (-8.76%)
Products, Strategic Combinations

Fate Therapeutics Announces Expansion Of Solid Tumor Collaboration With Ono Pharmaceutical For Off-The-Shelf, Ipsc-Derived Car Nk And Car T-Cell Cancer Immunotherapies

Published: 06/28/2022 11:32 GMT
Fate Therapeutics Inc (FATE) - Fate Therapeutics Announces Expansion of Solid Tumor Collaboration With Ono Pharmaceutical for Off-the-shelf, Ipsc-derived Car Nk and Car T-cell Cancer Immunotherapies.
Fate Therapeutics Inc - Expanded Partnership Enables Development of Both Car Nk and Car T-cell Collaboration Candidates for Solid Tumors.
Fate Therapeutics Inc - Fate Retains All Rights of Manufacture of Collaboration Products on a Global Basis.
Fate Therapeutics -under Deal, Co Retains Right to Jointly Develop, Commercialize Car Nk & Car T-cell Product Candidates in U.S., Europe.